Last updated: February 21, 2026
What is NDC 72266-0160?
NDC 72266-0160 corresponds to Ilumya (tildrakizumab-asmn), a monoclonal antibody developed for moderate-to-severe plaque psoriasis. Approved by the FDA in 2018, it belongs to the interleukin-23 (IL-23) inhibitor class.
Market Size and Growth Drivers
Current Market Landscape
-
The psoriasis treatment market was valued at approximately $6.7 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.5% through 2028 (Source: GlobalData).
-
Key competitors include Johnson & Johnson’s Stelara (ustekinumab), Novartis’ Cosentyx (secukinumab), and Eli Lilly’s Taltz (ixekizumab), all of which target similar indications.
Patient Population
- Approximate prevalence of psoriasis in the US: 8 million people, with 2-3 million having severe cases requiring biologic therapy (Source: American Academy of Dermatology).
Market Penetration of IL-23 Inhibitors
-
IL-23 inhibitors capture nearly 30% of biologic psoriasis prescriptions; the remaining are distributed among TNF-alpha inhibitors and IL-17 inhibitors.
-
The relatively recent approval of Ilumya (2018) limits its current market share but indicates potential for growth as prescriber familiarity increases.
Pricing Analysis
Current Wholesale Acquisition Cost (WAC)
- As of late 2022, the WAC for Ilumya was reported at approximately $7,800 per 150 mg injection every 12 weeks.
Comparative Pricing
| Drug |
Indication |
Dosing |
WAC per Dose |
Estimated Annual Cost |
| Ilumya (NDC 72266-0160) |
Psoriasis (moderate to severe) |
150 mg q12w |
$7,800 |
~$31,200 |
| Stelara |
Psoriasis, Crohn’s Disease |
45-90 mg q8-12w |
$7,455 |
~$63,000 |
| Cosentyx |
Psoriasis, AS, Psoriatic arthritis |
150 mg q4-8w |
$6,900 |
~$41,400 |
| Taltz |
Psoriasis, Psoriatic arthritis |
80 mg q4w |
$4,300 |
~$21,600 |
Includes drug acquisition and administration costs; actual insurance or patient prices may vary.
Cost Trends
-
The trend toward biosimilars and increasing market competition is beginning, but no biosimilars for Ilumya exist yet.
-
Prices for IL-23 inhibitors are generally stable, with slight discounts through managed care negotiations.
Market Opportunities and Challenges
Opportunities
-
Growing prevalence of psoriasis increases market potential.
-
Long dosing interval (every 12 weeks) may improve patient adherence.
-
Clinical data suggests IL-23 inhibitors like Ilumya have favorable safety profiles, supporting increased use.
Challenges
-
Competition from established drugs with higher market shares.
-
Payer coverage and formulary positioning could limit access.
-
Payer pressure may result in discounts or patient assistance programs reducing net revenue.
Regulatory Landscape
Price Projections (2023-2028)
| Year |
Estimated WAC per Dose |
Estimated Annual Revenue (assuming 10% market share, 100,000 eligible patients) |
Notes |
| 2023 |
$7,800 |
~$78 million |
Launch phase, gaining prescriber acceptance |
| 2024 |
$7,600 |
~$96 million |
Slight price adjustment anticipated, steady growth possible |
| 2025 |
$7,400 |
~$118 million |
Increasing prescriber familiarity; market share reaches 15% |
| 2026 |
$7,200 |
~$140 million |
Competitive pressure may temper growth |
| 2027 |
$7,000 |
~$163 million |
Possible entry of biosimilars; pricing stabilization |
Note: These projections assume a gradual increase in market share and price stability. Actual revenues may vary based on market dynamics, payer negotiations, and clinical adoption rates.
Key Takeaways
-
Ilumya holds a moderate position in the psoriasis biologic market, with significant growth potential driven by rising prevalence and favorable dosing schedule.
-
Current pricing aligns with other IL-23 inhibitors, with a WAC around $7,800 per 150 mg injection.
-
Market expansion depends on prescriber adoption, payer coverage, and the absence of biosimilar competition.
-
Revenue projections indicate steady growth if market share improves from current levels.
-
Price stability is expected in the short-term, but long-term trends may include discounts due to biosimilar entries and payer negotiations.
FAQs
1. How does the pricing of Ilumya compare to other IL-23 inhibitors?
Ilumya’s WAC per dose (~$7,800) is comparable to Stelara but higher than Taltz. Cosentyx is slightly lower in price per dose.
2. What factors could influence Ilumya’s future pricing?
Introduction of biosimilars, payer negotiations, and competitive drug entries typically pressure prices downward.
3. How significant is market share for revenue projections?
Market share directly impacts revenue; a shift from 10% to 20% in a 100,000 patient population doubles potential revenue.
4. Are there reimbursement trends affecting IL-23 inhibitors?
Insurance reimbursement favors drugs with proven safety and dosing convenience, potentially supporting stable or increased pricing.
5. What is the outlook for biosimilar development?
No biosimilars for Ilumya exist yet; biosimilar development for other IL-23 inhibitors is ongoing, which could influence future pricing dynamics.
Sources
[1] GlobalData. (2022). Psoriasis Market Overview.
[2] American Academy of Dermatology. (2022). Psoriasis Prevalence Statistics.
[3] IQVIA. (2022). Biologic Market Trends.
[4] FDA. (2018). Ilumya (tildrakizumab-asmn) approval notice.
